SEC Form 4 · accession 0001209191-17-066069
ADURO BIOTECH, INC. · ADRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dirk G. Brockstedt
Officer — EVP of Research and Dev.
Period of report
Dec 15, 2017
Accepted (ET)
Dec 15, 2017 · 8:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001435049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 15, 2017 | M | 64,108 | $1.45 | A | 137,826 | D | |
| Common StockF1 | Dec 15, 2017 | S | 65,223 | $8.1135 | D | 72,603 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.45 | Dec 15, 2017 | M | 64,108 | D | — | Jan 9, 2025 | Common Stock | 64,108 | 225,998 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.0 to $8.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015.